SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Serina Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.65−0.07 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $27.04M
- P/E (TTM)
- –
- Dividend yield
- –
Serina Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant revenues | $0 | – | $0 | $0 | $130.00K | $0 | – | $14.00K | $51.00K | $5.00K | $87.00K | $29.00K | – | -100.0% |
| Other Revenues [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $46.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Serina Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.